A Study of Famitinib in Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and
Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study
has shown that the toxicity is manageable.
The purpose of this study is to determine whether Famitinib can improve progression free
survival compared with placebo in patients with advanced colorectal cancer who failed in
previous at least two lines of chemotherapy.